CollPlant BiotechnologiesCLGN -0.03%35 PS Ratio is 11.22 as of Jul. 06, 2026, which is 3% below its 10-year median of 11.56. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, CollPlant Biotechnologies ranks worse than 52.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CollPlant Biotechnologies's share price is $0.3478.
CollPlant Biotechnologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.03. Hence, CollPlant Biotechnologies's PS Ratio for today is 11.22.
The historical rank and industry rank for CollPlant Biotechnologies's PS Ratio or its related term are showing as below:
CLGN'
s PS Ratio Range Over the Past 10 Years
Min: 2.76 Med: 11.56 Max: 481.11
Current: 11.22
During the past 13 years, CollPlant Biotechnologies's highest PS Ratio was 481.11. The lowest was 2.76. And the median was 11.56.
CLGN's PS Ratio is ranked worse than 52.85% of 929
companies
in the Biotechnology industry
Industry Median: 9.91
vs CLGN: 11.22
During the past 13 years, CollPlant Biotechnologies's highest 3-Year average Revenue per Share Growth Rate was 674.70% per year. The lowest was -67.50% per year. And the median was 4.60% per year.
Back to Basics: PS Ratio
CollPlant Biotechnologies (NAS:CLGN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CollPlant Biotechnologies PS Ratio Related Terms
CollPlant Biotechnologies PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CollPlant Biotechnologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CollPlant Biotechnologies's Share Price of today is $0.3478. CollPlant Biotechnologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CollPlant Biotechnologies (CLGN) has a PS Ratio of 11.22 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CollPlant Biotechnologies and its competitors. This is near median its historical median of 11.56. Over the past decade, CollPlant Biotechnologies' PS Ratio has ranged from 2.76 to 481.11. According to the industry distribution chart, CollPlant Biotechnologies ranks #491 out of 929 companies in the Biotechnology industry, placing it in the top 52.9%.
Is CollPlant Biotechnologies' PS Ratio too high?
CollPlant Biotechnologies' current PS Ratio of 11.22 is near median its 10-year median of 11.56. Over the past 10 years, this metric has ranged from a low of 2.76 to a high of 481.11. The Biotechnology industry median PS Ratio is 9.91. CollPlant Biotechnologies' value of 11.22 is 13.2% above this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #491 out of 929 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' PS Ratio compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #491 out of 929 companies for PS Ratio. This places CollPlant Biotechnologies in the lower half of its industry. The industry median PS Ratio is 9.91. CollPlant Biotechnologies' value of 11.22 is 13.2% above this benchmark. Historically, CollPlant Biotechnologies' own PS Ratio has ranged from 2.76 to 481.11 over the past decade. While the company's 10-year median is 11.56 vs. the industry median of 9.91, CollPlant Biotechnologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current PS Ratio of 11.22 is 13.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current PS Ratio is 11.22, which is near median its own 10-year median of 11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.35 — trading 19.9% above its estimated fair value. The current PS Ratio is 11.22, which is near median its 10-year median of 11.56 and 13.2% above the Biotechnology industry median of 9.91. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current PS Ratio is 11.22 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.35 is trading 19.9% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for CLGN:
PS Ratio: 11.22 (near median its 10-year median of 11.56)
GF Value™: $0.29 vs. price of $0.35 (19.9% above fair value)
Industry Position: 13.2% above the Biotechnology median (#491 of 929)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
